德拉曼尼德的实际使用:欧洲许可后安全研究的结果
N Schönfeld1, L Barkane2, I Davoliene3
1Helios Klinikum Emil von Behring, Berlin, Germany.
IJTLD open
|July 18, 2024
概括
这项研究在现实环境中评估了德拉曼尼德 (DLM) 对多药耐药结核病 (MDR-TB) 的治疗. 德拉曼尼德的治疗成功率为77%,副作用可控,证实了其安全性和有效性.
科学领域:
- 药物监督 药物监督 药物监督
- 传染性疾病 传染性疾病
- 临床药理学 临床药理学
背景情况:
- 德拉曼尼德 (DLM) 的许可后安全性研究 (PASS) 根据欧洲药物管理局 (EMA) 的承诺进行.
- 评估了DLM在多耐药结核病 (MDR-TB) 患者的实际使用,安全性和治疗结果.
研究的目的:
- 在现实世界MDR-TB患者群体中评估DLM的安全性和有效性.
- 监测不良事件和治疗成功率.
- 评估DLM使用超过24周.
主要方法:
- 欧盟的前性,多中心性,非干预性研究.
- 在DLM启动后最长30个月收集的数据.
- 用于分析的描述性统计数据.
主要成果:
- 包括86名MDR-TB患者;治疗成功率为77%.
- 最常见的不良药物反应: QT 间隔延长,这是可以管理的.
- 在一名患者中检测到DLM耐药性;没有发现新的安全问题.
结论:
- 在现实环境中,DLM是MDR-TB治疗的安全和有效方法.
- 延长QT间隔并没有引起显著的心脏问题.
- 治疗结果与世卫组织对欧洲的目标保持一致.
更多相关视频
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
29.0K
11:17Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
12.9K
相关概念视频
Pharmacovigilance
813
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
813
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Drugs for Treatment of Diarrhea-Predominant IBS
156
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
156
